Iovance Biotherapeutics Consensus Price Target Increased by 34.74% to $13.06
The average one-year price target for Iovance Biotherapeutics (NASDAQGM:IOVA) (DB:2LB) has been revised to $13.06 / share. This is an increase of 34.74% from the prior estimate of $9.69 dated September 11, 2026. These figures represent aggregate analyst targets compiled from multiple sources and do not constitute a recommendation by Fintel.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $6.06 to a high of $21.00 / share. The average price target represents a decrease of 8.25% from the latest reported closing price of $14.23 / share as of October 1, 2026.
The median target increased to $13.77 from $9.69 as of September 29, 2026. The current target range width is $14.94, which is a widening of +96.84% from the prior target range width of $7.59. Looking at the target history, the mean target was $13.06 on October 2, 2026, $9.69 on September 15, 2026, $9.69 on August 28, 2026, and $8.39 on August 4, 2026. The observed twelve-month high mean target was $13.06 on October 2, 2026, and the observed twelve-month low mean target was $7.90 on November 17, 2025. The target has changed by +45.45% since the 90-day baseline date of June 30, 2026.
In terms of price performance, the stock experienced a price change of +31.76% over one week, starting from a baseline close of $10.80 on September 24, 2026. Over one month, the price change was +71.86% from a baseline close of $8.28 on September 1, 2026. For its latest earnings report on August 6, 2026, the company reported an actual EPS of -0.11, compared to the estimated EPS of -0.1283. Actual revenue was $99,313,000.00, which was a +10.85% surprise compared to the estimated revenue of $89,589,150.00.
Iovance Biotherapeutics, Inc., based in the United States, operates within the Biotechnology sub-industry. The company focuses on pioneering novel cancer immunotherapies, notably developing tumor-infiltrating lymphocyte (TIL) products such as lifileucel for metastatic melanoma and LN-145 for cervical and head and neck cancers.
Recent analyst actions include Wells Fargo maintaining an Overweight rating on September 30, 2026. HC Wainwright & Co. maintained a Buy rating on September 29, 2026. Goldman Sachs reiterated a Buy rating on September 24, 2026, and Barclays maintained an Overweight rating on September 17, 2026. The recommendation trend for the period of September 1, 2026, shows a total of 15 recommendations, with 80.0% positive and 20.0% hold. This is unchanged from the prior recommendation period of August 1, 2026.
Within the Biotechnology sub-industry, 24 companies are covered. The targets were raised for 5 companies, lowered for 7, and remained unchanged for 12. The sub-industry median revision percent was 0.00%, and the median implied change percent was +81.91%.
The peer companies in the advanced cell therapy space, including Allogene Therapeutics, Caribou Biosciences, and Fate Therapeutics, all had unchanged target revisions of 0.00%, while maintaining positive implied changes.
| Company name | Target revision | Implied change |
|---|---|---|
| Allogene Therapeutics | 0.00% | +496.10% |
| Caribou Biosciences | 0.00% | +891.33% |
| Fate Therapeutics | 0.00% | +142.25% |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.